Abstract
Purpose. This study was conducted to examine the influence of P-glycoprotein (P-gp) modulation on the pharmacodynamics of the model opioid peptide DPDPE.
Methods. Mice (n = 5−7/group) were pretreated with a single oral dose of the P-gp inhibitor GF 120918 (25 or 250 mg/kg) or vehicle. 3H-DPDPE ( 1 0 mg/kg) or saline was administered 2.5 hr after pretreatment. Antinociception was determined, and blood and brain tissue were obtained, 10 min after DPDPE administration.
Results. A significant difference (p < 0.001) in DPDPE-associated antinociception was observed among mice pretreated with a 25- (83 ± 16% MPR) or 250- (95 ± 5% MPR) mg/kg dose of GF 120918 in comparison to mice pretreated with vehicle (24 ± 14% MPR) or mice receiving GF 120918 without DPDPE (12 ± 8% MPR). A significant difference (p < 0.0 1) in brain tissue DPDPE concentration also was observed among treatment groups [25 ± 6 ng/g (vehicle), 37 ± 11 ng/g (25 mg/kg GF 120918), 70 ± 8 ng/g (250 mg/kg GF 120918)]. In contrast, blood DPDPE concentrations were not statistically different between groups (678 ± 66, 677 ± 130, and 818 ± 236 ng/ml for vehicle, GF120918 [25 mg/kg], and GF120918 [250 mg/kg], respectively). A single 100-mg/kg i.p. dose of (+)verapamil increased the brain:blood DPDPE concentration ratio by ∼70% relative to saline-treated control mice (0.139 ± 0.021 vs. 0.0814 ± 0.0130, p < 0.01), a change in partitioning similar to that observed with the low dose of GF 120918. These data provide further support for a P-gp-based mechanism of brain:blood DPDPE distribution.
Conclusions. The present study demonstrates that GF 120918 modulates blood-brain disposition and antinociception of DPDPE. Coadministration of a P-gp inhibitor with DPDPE may improve the pharmacologic activity of this opioid peptide.
Similar content being viewed by others
REFERENCES
H. I. Mosberg, R. Hurst, V. J. Hruby, K. Gee, H. I. Yamamura, J. J. Galligan, and T. F. Burks. Bis-penicillamine possesses highly improved specificity toward delta opioid receptors. Natl. Acad. Sci. U.S.A. 80:5871–5874 (1983).
S. A. Williams, T. J. Abbruscato, V. J. Hruby, and T. P. Davis. Passage of a δ-opioid selective enkephalin, [D-penicillamine2,5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66:1289–1299 (1996).
S. J. Weber, D. L. Greene, S. D. Sharma, H. I. Yamamura, T. H. Kramer, T. F. Burks, V. J. Hruby, L. B. Hersh, and T. P. Davis. Distribution and antinociception of [3H]cyclic [D-Pen2, D-Pen5]-enkephalin and two halogenated analogs after intravenous administration J. Pharmacol. Exp. Ther. 259:1109–1117 (1991).
S. J. Weber, D. L. Greene, V. J. Hruby, H. I. Yamamura, F. Porreca, and T. P. Davis. Whole body and brain distribution of [3H]cyclic[D-Pen2, D-Pen5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263:1308–1316 (1992).
S. J. Weber, T. J. Abbruscato, E. A. Brownson, A. W. Lipkowski, R. Polt, A. Misicka, R. C. Haaseth, H. Bartosz, V. J. Hruby, and T. P. Davis. Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. J. Pharmacol. Exp. Ther. 266:1649–1655 (1993).
C. Chen and G. M. Pollack. Development of a capillary zone electrophoresis assay to examine the disposition of [D-pen2,5]enkephalin in rats. J. Chromatogr. Biomed. Appl. 681:363–373 (1996).
C. Chen and G. M. Pollack. Extensive biliary excretion of the model opioid peptide [D-Pen2,5]enkephalin in rats. Pharm. Res. 14:345–350 (1997).
M. V. Shah, K. L. Audus, and R. T. Borchardt. The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through blood-brain barrier Pharm. Res. 6:624–627 (1989).
C. Chen and G. M. Pollack. Blood-brain disposition and antinociceptive effects of [D-pen2,5]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 283:1151–1159 (1997).
C. F. Higgins. ABC transporters: from microorganisms to man. Ann. Rev. Cell. Biol. 67–113 (1992).
M. M. Gottesman and I. Pastan. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263:12163–12166 (1989).
B. L. Lum, M. P. Gosland, S. Kaubisch, and B. I. Sikic. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacother. 13:88–109 (1993).
B. L. Lum and M. P. Gosland. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol.-Oncol. Clinics North America 9:319–336 (1995).
R. C. Sharma, S. Inoue, J. Roitelman, R. T. Schimke, and R. D. Simoni. Peptide transport by the multidrug resistance pump. J. Biol. Chem. 267:5731–5734 (1992).
T. Saeki, K. Ueda, Y. Tanigawana, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:6077–6080 (1993).
A. H. Schinkel, E. Wagenaar, C. A. A. M. Mol, and L. Van Deemter. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517–2524 (1996).
R. Callaghan and J. R. Riordan. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268:16059–16064 (1993).
C. Chen and G. M. Pollack. Altered disposition and antinociception of [D-penicillamine2,5]enkephalin in the mdrla gene-deficient mice. J. Pharmacol. Exp. Ther. 287:545–552 (1998).
S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L. R. Brouwer. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:599–605 (1998).
J. M. Ford and W. N. Hait. Pharmacology of drug that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155–199 (1990).
M. V. Relling. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monitor. 18:350–356 (1996).
I. Pastan and M. M. Gottesman. Multidrug resistance. Ann. Rev. Med. 42:277–286 (1991).
B. Dumaitre and N. Dodic. Patent Application WO 92/12132 (1992).
F. Hyafil, C. Vergely, P. D. Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595–4602 (1994).
G. D. Pennock, W. S. Dalton, W. R. Roeske, C. P. Appleton, K. Mosley, P. Plezia, T. P. Miller, and S. E. Salmon. Systemic toxic effects associated with high-dose of verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst. 83:105–110 (1991).
H. H. Loh, L. F. Tseng, E. Wei, and C. H. Li. Beta-endorphin is a potent analgesic agent. Proc. Natl. Acad. Sci. U.S.A. 73:2895–2898 (1976).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, C., Pollack, G.M. Enhanced Antinociception of the Model Opioid Peptide [D-Penicillamine2,5] Enkephalin by P-Glycoprotein Modulation. Pharm Res 16, 296–301 (1999). https://doi.org/10.1023/A:1018892811980
Issue Date:
DOI: https://doi.org/10.1023/A:1018892811980